We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers.
- Authors
Alqassieh, Rami; Suleiman, Aiman; Abu-Halaweh, Sami; Santarisi, Abeer; Shatnawi, Omar; Shdaifat, Lara; Tarifi, Amjed; Al-Tamimi, Mohammad; Al-Shudifat, Abdel-Ellah; Alsmadi, Heba; Al Sharqawi, Ahmed; Alnawaiseh, Hadeel; Anasweh, Yara; Domaidah, Farah Abo; Jaber, Haneen Abu; Al-Zarir, Mohammad Rashid; Bsisu, Isam
- Abstract
COVID-19 (coronavirus disease 2019) vaccines induce immunity through different mechanisms. The aim of this study is to compare the titers of specific antibodies in subjects vaccinated with either the Pfizer-BioNTech COVID-19 vaccine or the Sinopharm vaccine. This prospective observational cohort included Jordanian adults vaccinated with two doses, 21 days apart, of either of the two aforementioned vaccines. Titers were collected 6 weeks after the administration of the second dose. Overall, 288 participants were included, of which 141 were administered the Pfizer-BioNTech vaccine, while 147 were administered the Sinopharm vaccine. Remarkably, 140 (99.3%) of the Pfizer-BioNTech vaccine recipients had positive IgG titers, while 126 (85.7%) of Sinopharm recipients had positive IgG (p < 0.001). The mean titer for IgG among Pfizer-BioNTech recipients was 515.5 ± 1143.5 BAU/mL, compared to 170.0 ± 230.0 BAU/mL among Sinopharm subjects (p < 0.001). Multivariable regression analysis showed that the Pfizer-BioNTech vaccine positively correlated with positive IgG titers (OR: 25.25; 95% CI: 3.25–196.15; p = 0.002), compared with a negative effect of cardiovascular diseases (OR: 0.33; 95% CI: 0.11–0.99; p = 0.48) on IgG titers. In conclusion, fully vaccinated recipients of the Pfizer-BioNTech vaccine had superior quantitative efficiency compared to Sinopharm recipients. A booster dose is supported for Sinopharm recipients, or those with chronic immunosuppressive diseases.
- Subjects
COVID-19; ANTIBODY titer; BOOSTER vaccines; COVID-19 vaccines; IMMUNOGLOBULIN G
- Publication
Vaccines, 2021, Vol 9, Issue 11, p1223
- ISSN
2076-393X
- Publication type
Article
- DOI
10.3390/vaccines9111223